Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

Piper Sandler analyst Kelsey Goodwin has initiated coverage on Relmada Therapeutics (NASDAQ: RLMD) with an Overweight rating. The firm has set a price target of $12 for the company's stock.